Pre-Conference Day - CET (Central European Time, GMT+01:00)
This workshop will focus on the scaling of RNA modalities to the clinic, addressing critical steps in transitioning from bench to GMP facility. Key process considerations, including optimal operations, quality control, cost efficiency, and equipment yields, will be explored. Participants will also examine the development of robust analytics to support scale-up activities and ensure successful manufacturing at clinical and commercial scales.
- Miroslav Gaparek - CEO, Sensible Biotechnologies
This workshop will provide an introduction to RNA therapeutics, covering the fundamental principles and the evolving industry landscape. Participants will gain insights into the science behind RNA-based modalities, including their mechanisms of action and therapeutic potential, while exploring current trends, market dynamics, and key players shaping the future of RNA therapeutics.
- Michael Hodges - CEO, 1Strand
This workshop will explore targeted delivery strategies for antisense oligonucleotides (ASOs), siRNA, and next-generation mRNA therapies, with a focus on applications in key tissues and organs such as the liver, lung, kidney, brain, and heart. Participants will examine innovative approaches to achieve precise delivery to these critical sites, addressing challenges in overcoming biological barriers, enhancing therapeutic efficacy, and minimizing off-target effects.
- Manuel Vega - CEO, AGS Therapeutics
This workshop is tailored for Biotech leaders and will explore key considerations at each stage of developing an RNA medicine. Topics will include funding strategies, building effective partnerships and collaborations, commercial planning, and team development. Participants will gain insights into navigating challenges and making strategic decisions to successfully advance RNA therapeutics from ideation to commercialization.
- Sonja Merkas, PhD - Founder, Creator and Doer, Livinovea
- Renee Williams - Founder and Managing Partner, Williams Biotech Consulting, LLC